News

Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy
A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...
News Medical on MSN12d
New advances in the fight against the most common form of lung cancer
Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...
Medscape3d
The Hypoxic Tumor Microenvironment: Driving the Tumorigenesis of Non-small-cell Lung Cancer
NSCLC can be further subdivided into: lung adenocarcinoma (ADC), large cell carcinoma and squamous cell carcinoma (SCC). These cancer subtypes have distinct morphologies and molecular profiles ...
CURE3d
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...
Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...
HealthDay on MSN1d
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
MONDAY, April 21, 2025 (HealthDay News) — Immunotherapy might help keep lung cancer at bay for months or even years after the ...
Fierce Pharma10d
Amgen pads Imdelltra's case in tough-to-treat lung cancer subtype with phase 3 survival win
Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...
EurekAlert!6d
Lung-MAP 3.0: Landmark trial expands genomic screening options for enrolling patients
Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...